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A patient who had received temozolomide (TMZ) as a single agent in treatment of malignant glioma developed therapy-induced
myelodysplasia (T-MDS). TMZ is an orally active imidazotetrazine which methylates guanine residues in DNA, ultimately causing
singleanddouble-strandDNAbreaksleadingtoapoptoticcelldeath.TMZdoesnotchemicallycross-linkDNAandisconsidereda
nonclassicalalkylatingagent,similarinstructureandactivitytodacarbazine.Observationsonthispatient,andonsimilarlytreated
others, suggest that the cumulative dose threshold (CDT) for TMZ that predisposes to T-MDS and which may potentially lead
to acute myeloid leukemia (T-AML) is around 18000 to 20000mg/sq m. Although the incidence of T-MDS and the predisposing
CDTofTMZmaydiﬀerfromthatofotherpotentiallyleukemogeniccompoundscurrentlyandformerlyusedaschemotherapeutic
agents, all alkylating agents, including TMZ, should be considered potentially leukemogenic when administered long term.
1.Introduction
Most instances of myelodysplasia (MDS) and acute myeloid
leukemia (AML) are de novo or primary illnesses, and occur
without known exogenous or environmental cause and at
an increasing incidence with advancing age [1–3]. Failure
of DNA repair mechanisms and the physiologic requirement
for programmed DNA fracture and chromosome reassem-
bly during normal hematopoiesis are possible endogenous
causes [1].
Secondary f o r m so fM D S / A M La r el e s sc o m m o na n d
may occur in the setting of pre-existing hematological or
systemic disorders, after exposure to environmental toxins,
or consequent to treatment of malignancy or circumstances
requiring prolonged immunosuppression [4–7]. More and
more cases of event-related or therapy-induced MDS/AML
are being recognized. Recent studies suggest that individuals
with this subset of secondary MDS/AML may have particular
predisposing genetic loci [8, 9]. It is generally believed that
secondaryformsofMDS/AMLaremorerefractorytotherapy
than are de novo illnesses, and as recently reported, even
with equivalent low-risk chromosome aberrations [10–12].
The bone marrow histopathology of T-MDS more often
shows multilineage dysplasia, ﬁbrosis and hypoplasia than
is observed in de novo forms of MDS making comparable
classiﬁcation diﬃcult along guidelines designed for de novo
MDS [12, 13]. This seems particularly true of examples
of secondary MDS consequent to excessive occupational
exposures to benzene, an obsolete chemotherapy drug [2,
14–17].
Alkylating agent-induced MDS/AML was ﬁrst described
after treatment of multiple myeloma with melphalan [18].
Many subsequent observations suggested that MDS/AML
after therapy with alkylating agents was not idiosyncratic,
but directly related to their cumulative dose, regardless
of mode of administration [19]. The clinical features of
such secondary AML syndromes include a MDS phase in
as many as 70% of cases [2, 4, 5]. By contrast, de novo
AML typically begins abruptly without a period of MDS.
There also appears to be a latency period and a window
of opportunity, from exposure to onset of hematologic
neoplasm, generally described as between 2 and 10 years
after a potentially leukemogenic CDT is reached [5]. Certain
cytogenetic aberrations in bone marrow cells are also more
likely to occur after exposure to alkylating agents. Such
aberrations involve variable losses of genetic material from
chromosomes 5 and 7 in as many as 50–70% of cases [2–
5, 10]. Moreover, some alkylating agents may be far more2 Advances in Hematology
leukemogenic than others, and the CDT for each compound
varies considerably [6, 7, 19, 20]. Expanded use of a newer
alkylatingagent,TMZ,developedtofacilitatecentralnervous
systemdrug penetration in patients with cerebral neoplasms,
has become a standard of care [21, 22]. Unfortunately, its
mechanism of action suggests major eﬃcacy only for central
nervous system tumors bearing speciﬁc genetic markers
[23, 24]. The increasing reports of MDS/AML syndromes
following the use of TMZ serve as a reminder that alkylating
agents cannot be safely used continuously and long-term
unless the intent is palliation, rather than cure.
2.CaseReport
A 64-year-old previously healthy right-handed man expe-
rienced the sudden onset of grand mal seizures. Cranial
CT scans demonstrated a small left temporal lobe lesion.
Microscopic examination after its excision showed histology
consistent with astrocytoma, and clear tumor margins. He
received postoperative radiation therapy, along with small
oral doses of TMZ as a radiosensitizer. This drug was
then continued at 200mg/sq m/day, 5 days each month,
for 18 courses (total dose, approximately 20,000mg/sq m
or 40,000mg). Pretreatment blood counts gave entirely
normal values. Transient leukopenia and thrombocytopenia
occurred during chemotherapy, but the patient did not
require use of hematological growth promoting factors or
blood component transfusion. His blood counts returned
to normal, but several months after completion of all
therapy, a mild pancytopenia became evident, and gradually
worsened. Three years after treatment, the peripheral blood
ﬁlm demonstrated macrocytosis and typical bilobed Pelger-
Huet granulocytes [25]. The bone marrow examination at
that time showed normal total cellularity but demonstrated
3% blast forms and trilineage dysplasia. Conventional cyto-
genetics and FISH (ﬂuorescent in situ hybridization)p r o b e s
conﬁrmed isolated monosomy 7 in 80% of the marrow
metaphasesandnoalterationsinchromosome5.Adiagnosis
of high-risk MDS was evident. Allogeneic bone marrow
transplantation was contemplated, but 5 months after his
diagnosis of MDS, recurrence of the brain tumor was
identiﬁed in the left frontal lobe behind the optic nerve. Re-
biopsy conﬁrmed astrocytoma, and he received additional
radiation therapy along with a course of azacitidine for his
MDS.Thislattertreatmentresultedinaseverepancytopenia,
but eight months later, his blood counts were considerably
improved from those obtained at the time of his bone
marrow examination, and he was essentially asymptomatic.
He died from progression of the cerebral neoplasm 43
months following its initial diagnosis without conversion
from MDS to AML.
3. Discussion
Kyle, in 1970, ﬁrst called attention to the leukemogenic
potential of the alkylating agent, melphalan, when used
in the treatment of multiple myeloma [18]. The impor-
tance of a CDT among alkylating agents as a cause of
secondary AML was soon appreciated with analysis of
studies reporting the incidence of AML following increasing
cycles of MOPP (mechlorethamine, vincristine, procar-
bazine, prednisone) chemotherapy for Hodgkin’s lymphoma
[19]. Greene emphasized the duration of treatment and the
total dose administered as predictive of a greater leukemic
risk following administration of cyclophosphamide, perhaps
the alkylating agent most thoroughly studied in regard to
secondary AML [26]. The potentially leukemogenic cumu-
lative dose for cyclophosphamide has been estimated at
20,000mg and is about ten-fold that seen with another well-
studied alkylating agent, chlorambucil [19]. The alkylating
agent/CDT concept in leukemogenesis has been reconﬁrmed
in a more recent study demonstrating the appearance of, and
abrupt rise in, the incidence of secondary AML in patients
treated for breast cancer and receiving cyclophosphamide in
doses above 8,000mg/sq m along with other agents [6]. This
increased risk of T-MDS/AML was not observed in patients
treated with lower doses. For other types of chemothera-
peutic agents that may cause secondary AML/MDS, such
as topoisomerase II inhibitors, the mean latency is shorter,
and diﬀerent chromosome aberrations such as balanced
translocations are common [4]. The existence of a CDT
is probable but less well-deﬁned since these agents are
often used in combination chemotherapy. Additionally, a
prodrome of MDS is far less common [2, 4, 5, 7, 11].
TMZ is a novel chemotherapy drug that is structurally
related to dacarbazine. It has the advantage of a rapid
absorption following oral administration with almost 100%
bioavailability. Moreover, drug levels in the central nervous
system are 30–40% of TMZ plasma concentrations [27, 28].
As such, this drug has gained much attention as front-
line therapy for malignant gliomas, for which eﬀective
therapy remains poor. TMZ does not undergo signiﬁcant
liver metabolism and hydrolyzes rapidly to form the active
alkylating metabolite in plasma.
TMZisconsideredanon-classicalalkylatingagentinthat
it does not cross-link DNA strands. Its metabolites methylate
DNA, particularly on guanine sites. The formation of O6-
methylguanine generates single and/or double strand DNA
breakswhentheaﬀectedcelllineattemptstorepairthisalter-
ation via mismatch repair mechanisms and apoptosis results.
O6–methylguanine-DNA methyltransferase (MGMT) plays
a critical role in protecting cells from alkylating agents that
target O6-guanine, including TMZ [29, 30]. This enzyme
transferstheinappropriatemethylgroupfromtheguanineto
a cysteine residue which signals for its proteasome-mediated
degradation destruction via an ubiquitination pathway [31].
Thus, TMZ mediated apoptosis appears to be especially
eﬀective in MGMT negative tumors or in tumors with a
hypermethylated MGMT promoter [28, 31]. For this reason
knowledge of the MGMT promoter status provides clinically
useful information regarding the potential eﬃcacy to TMZ
and other alkylating agents in a variety of tumor systems
[30]. Additional studies report that TMZ also induces cell
cycle arrest at the G2-M checkpoint and /or disrupts tubulin
formation [32, 33].
Lacking ability to cross-link DNA, TMZ has less direct
toxicity to hematopoietic progenitor cells than classicalAdvances in Hematology 3
Table 1: Estimated CDT for selected potentially leukemogenic agents.
Compound Activity CDT (mg/sq m) Latency to MDS/AML (yrs)
Temozolamide alkylating agent 18–20,000 0.75–3
Cyclophosphamide alkylating agent 8–10,000 2–10
Alkeran alkylating agent 80 2–10
Mechlorethamine alkylating agent 60 2–10
Etoposide topo II inhibitor 2,000 1–4
Mitoxantrone topo II inhibitor 60 0.50–5
Benzene unknown 46,000 2–10
alkylating agents. As a result, myelosuppression is relatively
mild and not often dose-limiting. However, scattered reports
describe prolonged myelosuppression and even aplastic ane-
mia, in addition to the delayed syndromes of T-MDS/AML
following therapy with TMZ [34–36]. Hypermethylation-
induced gene silencing is a feature of MDS and secondary
AML, in comparison with de novo AML and may have
something to do with the lack of response to standard
chemotherapy in these syndromes and could also favor the
induction of T-MDS/AML [37].
Currently, TMZ is used in treatment of various types
of gliomas, typically in concert with radiation therapy and
as a radiosensitizing agent [38]. In more recent reports,
it has been combined with other agents with diﬀerent
mechanisms of action in an attempt to ﬁnd a more
potent treatment advantage over radiation alone following
debulking neurosurgery [39, 40]. TMZ has also been studied
as a chemotherapeutic agent in melanoma and other solid
tumors and in hematological disorders but little clinical data
as yet exists.
The patient reported here received TMZ at a total dose
of 20,000mg/sq m prior to the diagnosis of T-MDS. In
another instance where TMZ was used primarily as a single
agent, the total dose administered before onset of T-MDS
was quite similar, at 18,750mg/sq m [41]. In a series of
7 patients with gliomas, all of whom received TMZ and
who later developed alkylating agent-induced MDS, 2 were
treated with TMZ alone at doses of 24,000 and 28,000mg/sq
m prior to T-MDS/AML. The median dose of TMZ in this
cohort was 18,000mg/sq m, but 5 of the 7 patients had also
received substantial therapy with other chemotherapeutic
agents [21]. In the patient reported here, and in the 3 addi-
tional patients previously reported who developed T-MDS
following TMZ alone, MDS was conﬁrmed 28 to 36 months
followingtreatment.AdditionaloccurrencesofT-MDS/AML
in patients receiving TMZ in the treatment of gliomas
have been described, but the use of multiple chemotherapy
drugs in these patients prevents any conclusions about the
contributions of individual compounds [42, 43].
Benzene is an obsolete chemotherapeutic agent brieﬂy
used in the early approach to treatment of chronic myeloid
leukemia [1]. It continues to be of major scientiﬁc interest
because it is a well-known potential cause of secondary
MDS/AML via occupational exposures at high cumulative
dose levels [1, 2, 44–47]. Its mechanism of action is
unknown, but it has been termed a radiomimetic compound
because of the similarity in the myeloid cell chromosome
aberrations it may produce to those identiﬁed after both
therapeutic radiation exposure and following treatment
with alkylating agents. Some of the metabolites of benzene
also exhibit anti-topoisomerase II activity, the importance
of which in terms of its mechanism of leukemogenesis
is debated [44–46]. Regulatory agencies, epidemiological
studies and peer-reviewed medical literature typically cite
cumulative benzene exposures in excess of 40ppm years
as the minimum exposure required to potentially cause
secondary MDS/AML [2, 47, 48]. However, exposure levels
well in excess of these values may not result in a statistically
signiﬁcant excess incidence of AML [49, 50].
In order to compare potentially leukemogenic doses of
benzene with those of other chemicals, the typical exposure
metric of ppm-years must be converted to the more clinically
relevant mg/sq m. An estimate of the mg absorbed dose
of benzene given a constant 1ppm (32mg/m3 =1ppm)
inhalation over an 8 hour daily work schedule during a
250 day work year and continuing over a 40 year period
employing standard measurements for respiratory rate, tidal
volume and absorbed dose, would yield a value around
92,000mg. Assuming the worker measured 2sq m in body
surface area, this would suggest that the minimum CDT
necessary to predispose to secondary MDS/AML would be
about 46,000mg/sq m. With controls on the amount of
benzene allowable as a trace contaminant in modern sol-
vents, it has become more diﬃcult to achieve the cumulative
dose levels required to initiate leukemogenesis in workers in
developed countries [51]. The wide range of the estimated
CDT necessary to predispose to secondary MDS/AML for
selected and well-studied modern chemotherapeutic agents
including TMZ and in comparison with benzene is shown in
Table 1 [6, 7, 18–20, 26, 47].
Most individuals receiving exceptionally large doses of
alkylating agents over an extended period do not develop
T-MDS/AML. This also is true in patients receiving TMZ
[22]. However, considering the limited survival of those
with malignant gliomas, in comparison with the wide range
of latency in alkylating agent-induced MDS/AML, it is
understandable why more examples of this hematological
complication have not been described. This relatively short
survival interval also makes it more diﬃcult to compare the
incidence of leukemogenesis from TMZ with that caused
by alkylating agents commonly used in the treatment of
neoplasms which are associated with a long survival, such4 Advances in Hematology
as Hodgkin’s lymphoma, testicular cancer and breast cancer.
Nevertheless, patients and their physicians should be aware
that prolonged use of TMZ as a single agent is not innocuous
and carries the potential to cause T-MDS/AML. The CDT
thatpredisposes to thesehematologicalsyndromes estimated
on limited case material appears to be around 18,000 to
20,000mg/sq m. Based on the extensive medical literature on
the subject, any alkylating agent in long-term administration
must always be considered potentially leukemogenic.
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